Resultados da pesquisa - Werner Engl

  • A mostrar 1 - 8 resultados de 8
Refinar resultados
  1. 1
    Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

    Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies Por Rolf Gustafson, Ann Gardulf, Susanne V. Hansen, Heinz Leibl, Werner Engl, Magdalena Lindén, Anne Müller, Lennart Hammarström

    Publicado em 2008
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A

    Extended half‐life pegylated, full‐length recombinant factor <scp>VIII</scp> for prophylaxis in children with severe haemophilia A Por Eric S. Mullins, Oleksandra Stasyshyn, María Román, David Osman, Ri Liesner, Werner Engl, Marlies Sharkhawy, Brigitt E. Abbuehl

    Publicado em 2016
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

    Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study Por Robert Klamroth, Jerzy Windyga, Vlad C. Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha Tangada, William Savage, Bruce M. Ewenstein

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

    Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies Por Michael Borte, G. Kriván, Beáta Dérfalvi, László Maródi, Thomas Harrer, Stephen Jolles, Christelle Bourgeois, Werner Engl, Heinz Leibl, Barbara McCoy, David Gelmont, Leman Yel

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

    Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Por Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Sudhir Gupta, Jennifer M. Puck, Werner Engl, Heinz Leibl, Barbara McCoy, Victoria Empson, David Gelmont, Richard I. Schiff

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

    Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A Por Barbara A. Konkle, Oleksandra Stasyshyn, Pratima Chowdary, David Bevan, Tim Mant, Midori Shima, Werner Engl, Jacqueline Dyck-Jones, Monika Fuerlinger, Lisa Patrone, Bruce M. Ewenstein, Brigitt E. Abbuehl

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

    Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency Por Richard L. Wasserman, Isaac Melamed, Mark R. Stein, Werner Engl, Marlies Sharkhawy, Heinz Leibl, Jennifer M. Puck, Arye Rubinstein, Lisa Kobrynski, Sudhir Gupta, Andrew J. Grant, Anoshie Ratnayake, Wendell Richmond, Joseph A. Church, Leman Yel, David Gelmont

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial Por Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar, Edward H. Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, T. T. Yee, Robert Klamroth, Wing-Yen Wong, Miranda Chapman, Werner Engl, Peter L. Turecek, Tobias M. Suiter, Bruce M. Ewenstein

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: